Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Evogene Ltd. (EVGN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/23/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Lavie Bio Investor Presentation"
08/17/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Rehovot, Israel – August 17, 2023 – Evogene Ltd. , a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, today announced its financial results for the second quarter period ended June 30, 2023. Ofer Haviv, Evogene’s President and Chief Executive Officer, stated: “The second quarter of 2023 marked a period of remarkable achievements for the Evogene group. It was a pivotal point in the transformation that Evogene has been undergoing since the creation of our three AI tech engines in 2019. Listing some of the main achievements in this period: announcing the receiving of purchase orders in the aggregate amount of $11.3 million for Casterra's ..."
08/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Ag Plenus Investor Presentation"
07/18/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
07/17/2023 6-K Quarterly results
07/17/2023 6-K Quarterly results
07/17/2023 6-K Quarterly results
07/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Rehovot, Israel – July 3, 2023 – Casterra Ag Ltd. , an integrated castor cultivation solution company and a subsidiary of Evogene Ltd. , today announced additional $2.2 million of purchase orders to supply castor seeds during 2023, for new African territories. Casterra's castor seeds, developed with Evogene's GeneRator AI"
05/18/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Evogene Investor Presentation"
05/18/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Rehovot, Israel – May 18, 2023 – Evogene Ltd. ,"
05/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
05/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Rehovot, Israel – May 9, 2023 – The Ag-Seed Division of Evogene Ltd."
05/04/2023 6-K Quarterly results
05/03/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
04/27/2023 6-K Quarterly results
03/30/2023 6-K/A Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]
03/29/2023 6-K Quarterly results
03/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Rehovot, Israel – March 9, 2023 – Evogene Ltd. , a leading computational biology company targeting to revolutionize life-science based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, today announced its financial results for the fourth quarter and full year period ending December 31, 2022."
01/19/2023 6-K Quarterly results
01/12/2023 6-K Quarterly results
12/21/2022 6-K Quarterly results
12/08/2022 6-K Quarterly results
11/17/2022 6-K Quarterly results
11/14/2022 6-K Quarterly results
11/10/2022 6-K Quarterly results
11/03/2022 6-K Quarterly results
10/12/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Rehovot, Israel – October 12, 2022"
09/21/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Rehovot, Israel – September 21, 2022"
09/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
09/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Evogene Investor Presentation"
09/14/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
09/08/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
09/07/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"CURRENT ASSETS: Cash and cash equivalents $ 28,867 $ 32,325 Short-term bank deposits - 3,000 Marketable securities 6,383 18,541 Trade receivables 111 281 Inventories 162 92 Other receivables and prepaid expenses 2,182 2,651 37,705 56,890 LONG-TERM ASSETS: Long-term deposits 24 25 Right-of-use-assets 1,808 2,109 Property, plant and equipment, net 2,495 2,073 Intangible assets, net 14,630 15,207 18,957 19,414 $ 56,662 $ 76,304 CURRENT LIABILITIES: Trade payables $ 1,324 $ 1,463 Employees and payroll accruals 2,384 2,662 Lease liability 754 974 Liabilities in respect of government grants 126 89 Deferred revenues and other advances 16 175 Other payables 937 1,519 5,541 6,882 LONG-TERM LIABILITIES: Lease liability 1,367 1,695 Liabilities in respect of government grants 4,357 4,307 5,724 6,002 S..."
08/31/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Rehovot, Israel – August 31, 2022 – Evogene Ltd. , a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today its financial results for the second quarter ended June 30, 2022. Mr. Ofer Haviv, Evogene's President and Chief Executive Officer, stated, “We are very pleased with the two recent important developments that have taken place at the Evogene group: namely, the strategic collaboration and $10 million investment by ICL, a leading global specialty minerals company, into our subsidiary, Lavie Bio; as well as the launch of the Phase I first in human clinical trial, by our subsidiary, Biomica.” “The strategic collaboration between ICL and Lavie Bio and $10 million investment, combines La..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy